Furthermore, the confirmation that some triple-negative breast cancers (TNBC) are phenotypically similar to breast tumors with BRCA1 mutations has aroused the interest of researchers to study the effectiveness of PARP inhibitors in both BC with BRCA1/2 germline mutations and TNBC [12]. This evidence concerns the gene BRCA1 and breast neoplasm.